RNA therapeutics

The durability and capacity to boost protein expression of circular RNA makes it a promising candidate for next-generation vaccines and gene therapies.

Alnylam Pharmaceuticals develops therapeutics based on the RNA interference (RNAi) pathway discovered in 1998.

Paolo Martini leads the biotech company’s rare disease research program with the hope of developing the very first treatments for genetic metabolic disorders.

Nanoparticles fuse with cells to deliver their gene or RNA therapy cargo, but some are better shuttles than others. Now, scientists have developed a way to find the best nanoparticles for the job.

Anna Blakney, an RNA bioengineer and TikTok science communicator, studies how self-amplifying RNA improves RNA vaccines and therapeutics.

Nanoparticles that successfully deliver drugs in mice often fail in humans. To understand how nanoparticles fare across different model species, scientists developed a high-throughput system to screen nanoparticles in mice with humanized livers with the hope of better predicting nanoparticles that work in humans.